Company intelligence / Profile preview

KaNDy Therapeutics

Stevenage, Hertfordshire, United Kingdomforbion.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Completed Phase 2b with NT-814, showing positive data for the treatment of frequent symptoms of menopause, hot flashes and night sweats (vasomotor symptoms)[6][10]

Therapeutic areas: Women's Health
Modalities: Small molecules (NT-814, a neurokinin-1,3 receptor antagonist)
Industry: Biotech

Drug pipeline

1 asset

NT-814

Phase 2

Indications: Menopausal vasomotor symptoms

Beyond the preview

Go deeper on KaNDy Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KaNDy Therapeutics.

Explore the full profile